The frameshift polymorphism CYP3A43-74-delA is associated with poor differentiation of breast tumors

Cancer

Volumn 116, Issue 23, 2010, Pages 5358-5364

  Justenhoven, Christina ^a,b   Winter, Stefan ^a,b   Hamann, Ute ^c   Haas, Susanne ^d,e   Fischer, Hans Peter ^d   Pesch, Beate ^f   Brüning, Thomas ^f   Ko, Yon Dschun ^g   Brauch, Hiltrud ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e HSK Kliniken GmbH   (Germany)

^f ST JOSEF HOSPITAL   (Germany)

^g Johanniter Krankenhaus   (Germany)

Author keywords

breast cancer; CYP3A43; polymorphism; tumor grade

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A43; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST TUMOR; CANCER GRADING; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ORAL CONTRACEPTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78649612743     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25508     Document Type: Article

References (28)

1. Guengerich FP,. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999; 39: 1-17.
2. Huang Z, Fasco MJ, Figge HL, et al. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996; 24: 899-905.
3. Keshava C, McCanlies EC, Weston A,. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004; 160: 825-841.
4. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994; 4: 247-259.
5. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270: 414-423.
6. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987; 80: 1029-1036.
7. Burk O, Wojnowski L,. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369: 105-124.
8. Spurdle AB, Goodwin B, Hodgson E, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002; 12: 355-366.
9. Pawlak KJ, Wiebe JP,. Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J Steroid Biochem Mol Biol. 2007; 107: 172-179.
10. Poutanen M, Isomaa V, Peltoketo H, et al. Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol. 1995; 55: 525-532.
11. Wiebe JP,. Progesterone metabolites in breast cancer. Endocr Relat Cancer. 2006; 13: 717-738.
12. Wiebe JP, Souter L, Zhang G,. Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006; 100: 129-140.
13. Zumoff B,. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med. 1998; 217: 30-37.
14. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol. 2006; 24: 1823-1830.
15. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of 9 prospective studies. J Natl Cancer Inst. 2002; 94: 606-616.
16. Daly AK,. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006; 45: 13-31.
17. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11: 7369-7375.
18. Gellner K, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001; 11: 111-121.
19. Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 2001; 281: 1349-1355.
20. Stone A, Ratnasinghe LD, Emerson GL, et al. CYP3A43 ProAla polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1257-1261.
21. Rebbeck TR, Rennert H, Walker AH, et al. Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer. 2008; 123: 1385-1389.
22. Cauffiez C, Lo-Guidice JM, Chevalier D, et al. First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum Mutat. 2004; 23: 101.
23. Justenhoven C, Pierl CB, Haas S, et al. The CYP1B1- 1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2008; 111: 171-177.
24. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol. 2005; 20: 699-711.
25. Justenhoven C, Hamann U, Pesch B, et al. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev. 2004; 13: 2059-2064.
26. Domanski TL, Finta C, Halpert JR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001; 59: 386-392.
27. Finta C, Zaphiropoulos PG,. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene. 2000; 260: 13-23.
28. Isler JA, Vesterqvist OE, Burczynski ME,. Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics. 2007; 8: 353-368.